Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SPRY
Strong SellARS Pharmaceuticals, Inc. · Healthcare · United States · $586M · Avg Vol: $13M/d
COMPANY DESCRIPTION
ARS Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for severe allergic reactions, including anaphylaxis. Its lead product candidate, neffy, is an innovative intranasal epinephrine spray designed to offer a needle-free and convenient alternative to existing injectable treatments. The company aims to address a critical unmet medical need by providing a potentially more accessible and user-friendly emergency treatment option.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.3M | 30.0K | 89.1M | 84.3M | 300.1% | 116.9M | 132.3M | 195.7M | 52.4% |
| EPS | -0.87 | -0.57 | 0.08 | -1.74 | — | -2.18 | -1.84 | -0.89 | — |
| Shares | 93.9M | 96.4M | 98.0M | 99.3M | +5.7% | 99.4M | — | — | — |
| Debt | 0.5M | 0.3M | 42.0K | 96.4M | 485.2% | 171.6M | — | — | — |
| Equity | 272.9M | 230.8M | 256.8M | 114.3M | -25.2% | — | — | — | — |
| Op CF | -40.1M | -59.3M | 13.5M | -170.9M | — | -196.4M | — | — | — |
| Inv CF | -0.2M | -87.2M | -106.1M | 56.8M | — | — | — | — | — |
| Fin CF | 190.7M | 6.9M | 72.4M | 104.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SPRY are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SPRY | ARS Pharmaceuticals, Inc.(you) | $586M | 8 | Strong Sell |
| BLSM | BlossomHill Therapeutics, Inc. | $569M | 9 | Strong Sell |
| EIKN | Eikon Therapeutics, Inc. | $595M | 10 | Strong Sell |
| ALLO | Allogene Therapeutics, Inc. | $698M | 9 | Strong Sell |
| EVMN | Evommune, Inc. | $480M | 9 | Strong Sell |
| RGNX | REGENXBIO Inc. | $638M | 12 | Strong Sell |
| CAPR | Capricor Therapeutics, Inc. | $558M | 3 | Strong Sell |
| VOGX | Vogenx, Inc. | $504M | 5 | Strong Sell |
| KYTX | Kyverna Therapeutics, Inc. | $518M | 12 | Strong Sell |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $701M | 12 | Strong Sell |
Peer medians: ROE -25.6% · P/E 28.9x · Gross margin 58.7%